Future Market Insights.png
Treatment-Resistant Depression Therapeutics Market Value to reach US$ 4 Billion by 2033; NMDA Drugs to account for 49% of all Treatments: Future Market Insights, Inc. Report
December 16, 2022 02:30 ET | Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The global Treatment-Resistant Depression Therapeutics Market is experiencing rapid growth as the prevalence of depression and anxiety disorders...
axsomelogo-468x57.jpg
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
January 22, 2020 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 07, 2019 07:00 ET | Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...
axsomelogo-468x57.jpg
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
June 24, 2019 07:00 ET | Axsome Therapeutics, Inc.
First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting
May 06, 2019 06:30 ET | Axsome Therapeutics, Inc.
Previously completed active-controlled ASCEND trial in MDD now considered as pivotal; sufficient with ongoing STRIDE-1 Phase 3 trial for NDA in MDD Target randomization for STRIDE-1 Phase 3 trial...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
January 07, 2019 06:00 ET | Axsome Therapeutics, Inc.
Demonstrated statistically significant improvement in MADRS scores compared to active comparator (p<0.001 on primary endpoint) Rapid improvement in depressive symptoms demonstrating statistically...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
August 08, 2018 07:00 ET | Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 ...
axsomelogo-468x57.jpg
Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder
June 05, 2018 07:00 ET | Axsome Therapeutics, Inc.
First patient enrolled in the ASCEND study Trials in two mood disorders now underway with AXS-05 NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting
May 29, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present at the 2018 BIO International Convention
May 22, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...